153 related articles for article (PubMed ID: 34188983)
41. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study.
Nyakyoma K; Morriss R
Psychopharmacol Bull; 2010; 43(2):67-81. PubMed ID: 21052043
[TBL] [Abstract][Full Text] [Related]
43. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis.
Sharif ZA; Raza A; Ratakonda SS
J Clin Psychiatry; 2000 Jul; 61(7):498-504. PubMed ID: 10937608
[TBL] [Abstract][Full Text] [Related]
44. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
45. Treatment-resistant schizophrenia--the role of clozapine.
Meltzer HY
Curr Med Res Opin; 1997; 14(1):1-20. PubMed ID: 9524789
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders.
Clark RE; Teague GB; Ricketts SK; Bush PW; Xie H; McGuire TG; Drake RE; McHugo GJ; Keller AM; Zubkoff M
Health Serv Res; 1998 Dec; 33(5 Pt 1):1285-308. PubMed ID: 9865221
[TBL] [Abstract][Full Text] [Related]
47. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of treatment-resistant psychoses in the community: A naturalistic study.
Beck K; McCutcheon R; Stephenson L; Schilderman M; Patel N; Ramsay R; Howes OD
J Psychopharmacol; 2019 Oct; 33(10):1248-1253. PubMed ID: 31241396
[TBL] [Abstract][Full Text] [Related]
49. Experience with clozapine in a community mental health care setting.
Connelly JC; Fullick J
South Med J; 1998 Sep; 91(9):838-41. PubMed ID: 9743054
[TBL] [Abstract][Full Text] [Related]
50. Assertive community treatment as an alternative to incarceration for American pretrial detainees.
Zampella B; Talton S; Lam J; Khan A; Bryant T; Kunz M
Int J Law Psychiatry; 2024; 94():101990. PubMed ID: 38663174
[TBL] [Abstract][Full Text] [Related]
51. Does Assertive Community Treatment Reduce the Use of Compulsory Admissions?
Aagaard J; Tuszewski B; Kølbæk P
Arch Psychiatr Nurs; 2017 Dec; 31(6):641-646. PubMed ID: 29179833
[TBL] [Abstract][Full Text] [Related]
52. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
[TBL] [Abstract][Full Text] [Related]
53. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.
Siskind DJ; Harris M; Phillipou A; Morgan VA; Waterreus A; Galletly C; Carr VJ; Harvey C; Castle D
Epidemiol Psychiatr Sci; 2017 Jun; 26(3):325-337. PubMed ID: 27426892
[TBL] [Abstract][Full Text] [Related]
54. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
55. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
56. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
Fitton A; Benfield P
Pharmacoeconomics; 1993 Aug; 4(2):131-56. PubMed ID: 10146973
[TBL] [Abstract][Full Text] [Related]
57. Automated telehealth for managing psychiatric instability in people with serious mental illness.
Pratt SI; Naslund JA; Wolfe RS; Santos M; Bartels SJ
J Ment Health; 2015; 24(5):261-5. PubMed ID: 24988132
[TBL] [Abstract][Full Text] [Related]
58. [Leponex, 10 years after -- a clinical review].
Llorca PM; Pere JJ
Encephale; 2004; 30(5):474-91. PubMed ID: 15627052
[TBL] [Abstract][Full Text] [Related]
59. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
[TBL] [Abstract][Full Text] [Related]
60. Modified assertive community treatment program for patients with schizophrenia: Effectiveness and perspectives of service consumers from a South Indian setting.
Arahanthabailu P; Purohith AN; Kanakode R; Praharaj SK; Bhandary RP; Venkata Narasimha Sharma PS
Asian J Psychiatr; 2022 Jul; 73():103102. PubMed ID: 35452965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
